PharmaEngine - Asset Resilience Ratio
PharmaEngine (4162) has an Asset Resilience Ratio of 62.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PharmaEngine PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how PharmaEngine's Asset Resilience Ratio has changed over time. See PharmaEngine (4162) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down PharmaEngine's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PharmaEngine market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$3.09 Billion | 62.91% |
| Total Liquid Assets | NT$3.09 Billion | 62.91% |
Asset Resilience Insights
- Very High Liquidity: PharmaEngine maintains exceptional liquid asset reserves at 62.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PharmaEngine Industry Peers by Asset Resilience Ratio
Compare PharmaEngine's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for PharmaEngine (2009–2024)
The table below shows the annual Asset Resilience Ratio data for PharmaEngine.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.03% | NT$2.87 Billion ≈ $90.33 Million |
NT$5.85 Billion ≈ $184.24 Million |
-20.58pp |
| 2023-12-31 | 69.61% | NT$2.75 Billion ≈ $86.72 Million |
NT$3.95 Billion ≈ $124.57 Million |
+21.90pp |
| 2022-12-31 | 47.71% | NT$1.89 Billion ≈ $59.62 Million |
NT$3.97 Billion ≈ $124.97 Million |
+6.41pp |
| 2021-12-31 | 41.30% | NT$1.66 Billion ≈ $52.39 Million |
NT$4.03 Billion ≈ $126.85 Million |
+4.27pp |
| 2020-12-31 | 37.03% | NT$1.56 Billion ≈ $49.09 Million |
NT$4.21 Billion ≈ $132.54 Million |
-54.17pp |
| 2019-12-31 | 91.20% | NT$3.32 Billion ≈ $104.69 Million |
NT$3.64 Billion ≈ $114.79 Million |
+5.30pp |
| 2018-12-31 | 85.90% | NT$3.30 Billion ≈ $104.11 Million |
NT$3.85 Billion ≈ $121.19 Million |
+20.16pp |
| 2017-12-31 | 65.74% | NT$2.70 Billion ≈ $85.15 Million |
NT$4.11 Billion ≈ $129.52 Million |
+13.52pp |
| 2016-12-31 | 52.23% | NT$2.07 Billion ≈ $65.14 Million |
NT$3.96 Billion ≈ $124.74 Million |
-31.76pp |
| 2015-12-31 | 83.98% | NT$2.72 Billion ≈ $85.69 Million |
NT$3.24 Billion ≈ $102.03 Million |
+79.02pp |
| 2010-12-31 | 4.96% | NT$4.72 Million ≈ $148.86K |
NT$95.27 Million ≈ $3.00 Million |
-50.08pp |
| 2009-12-31 | 55.04% | NT$23.00 Million ≈ $724.63K |
NT$41.79 Million ≈ $1.32 Million |
-- |
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more